| Trial ID: | L0312 |
| Source ID: | NCT02923154
|
| Associated Drug: |
MT-3995
|
| Title: |
Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NASH
|
| Interventions: |
Drug: MT-3995|Drug: Placebo
|
| Outcome Measures: |
Percent change from baseline in ALT|Change from baseline in ALT|Adverse events
|
| Sponsor/Collaborators: |
Mitsubishi Tanabe Pharma Corporation
|
| Gender: |
All
|
| Age: |
20 Years to 75 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
48
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
September 2016
|
| Completion Date: |
April 2019
|
| Results First Posted: |
--
|
| Last Update Posted: |
September 6, 2019
|
| Locations: |
Investigational site, Kanagawa, Japan|Investigational site, Osaka, Japan
|
| URL: |
https://ClinicalTrials.gov/show/NCT02923154
|
